Donald Howard, MD
Sleep Medicine · Spokane, WANPI 1376590778
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,825 of the $4,747 with a category attached, or 80.6%. Omeros Corporation accounts for 80.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $3,825 and has fallen 97.4% since, to $100 in 2025.
Across 44 payments — averaging $107.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$4K
- Harmony Biosciences LLC$279
- GSK$197
- Inspire Medical Systems, Inc.$127
- Jazz Pharmaceuticals Inc.$116
- Philips North America LLC$78
- plus $125 from 4 others
Across 1 payment — averaging $6935.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$7K
What the payments were for
- Consulting fees$3,82581%
- Food & beverage$72215%
- Education$2004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 1 | $3,825 |
| Harmony Biosciences LLC | 2 | $279 |
| GSK | 26 | $197 |
| Inspire Medical Systems, Inc. | 1 | $127 |
| Jazz Pharmaceuticals Inc. | 2 | $116 |
| Philips North America LLC | 3 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $59 |
| AstraZeneca | 2 | $29 |
| Fisher & Paykel Healthcare Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,747 in reported general payments places this provider in the 85th percentile of 67 sleep medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 39 | $729,471 |
| Sodium Oxybate | 34 | $565,158 |
| XyremSodium Oxybate | 14 | $225,914 |
| SunosiSolriamfetol Hcl | 27 | $27,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,925 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 193 | $9,390 |
| Dextroamphetamine Sulfate | 68 | $8,661 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 55 | $7,660 |
| Modafinil | 92 | $6,308 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 38 | $4,361 |
| Gabapentin | 158 | $2,933 |
| Methylphenidate Hcl | 44 | $2,593 |
| Theophylline ErTheophylline Anhydrous | 12 | $1,627 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 49 | $980 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $197 | $12,92521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 sleep medicine providers in Washington.
Other sleep medicine in Spokane
- Todd GreenSpokane$284
- Muhammad UsamaAuburn$73K
- Vrushali GersappeEverett$56K
- Gandis MazeikaEdmonds$30K
- Meredith BroderickBellevue$8K
- Akhil RaghuramVancouver$7K
- Zeyad MorcosKirkland$6K
- Flavia ConsensSeattle$5K
- Ken HeSeattle$5K
- Teresa JacobsBellevue$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.